Proposed Method for Mass Spectrometric Measurement of the Gonadotropin-Releasing Hormone Agonist Deslorelin.
The study presents a method for measuring deslorelin in serum samples, achieving a detectability of less than 1 ppb, which may enhance analytical capabilities in veterinary medicine.
Where it sits
this study against the rest of the triptorelin corpusSummary and findings
The study proposes a method for measuring the peptide GnRH agonist deslorelin using mass spectrometry. The method involves cleaving a unique portion of the carboxy terminus and analyzing the resulting product. The proposed technique aims to improve detection sensitivity in serum samples from various animals.
Abstract
Deslorelin (C<sub>64</sub>H<sub>83</sub>N<sub>17</sub>O<sub>12</sub>) is a peptide GnRH agonist drug with monoisotopic mass 1281.64 Da applied as a drug-releasing implant in veterinary medicine for promoting ovulation and male/female contraception. Despite relative safety, it is suspected of reproductive toxicity and potential harm to unborn or breast-fed children. The compound was designed for high potency and prolonged half-life making it difficult to measure quantitatively in serum. A deslorelin LC-MS/MS method relies on detecting unmetabolized undegraded intact peptide, a crucial consideration since certain metabolites are thought to have activity. We propose a method for analyzing deslorelin indirectly by cleaving a unique portion of the carboxy terminus containing the modified proline ProNHEt (N-ethyl-2-pyrrolidine carboxamide), which can be removed by Clostridiopeptidase specific for arginine bonds. ProNHEt can be extracted from digested serum, reacted to an N-t-butyldimethylsilyl derivative and analyzed by GC-MS/MS. Settings were optimized for detectability to <1 ppb, and derivatization gave maximum yields by adjustment of solvent, reaction time, temperature and additives. MALDI-TOF applied to deslorelin revealed binding by copper. The proposed method can be used to measure deslorelin in serum samples from various zoo and small animals. Detection of deslorelin by examination of released ProNHEt is proposed to have applicability to other GnRH superagonists such as triptorelin and deslorelin breakdown products that exhibit the ProNHEt structure.
Background
The paper addresses the challenge of quantitatively measuring deslorelin, a GnRH agonist used in veterinary medicine, particularly due to its high potency and prolonged half-life. Previous methods may not adequately account for the activity of certain metabolites. This study is significant as it proposes a novel mass spectrometric method to improve detection of deslorelin in serum samples.
Methods
The proposed method involves cleaving a unique portion of deslorelin's carboxy terminus using Clostridiopeptidase specific for arginine bonds. The cleaved product, ProNHEt, is then extracted from digested serum and analyzed by GC-MS/MS. Specific settings were optimized for maximum detectability and yield.
Results
The method achieved a detectability of <1 ppb for deslorelin. MALDI-TOF analysis indicated that deslorelin binds to copper. The method is suggested to be applicable to other GnRH superagonists.
Interpretation
The proposed method offers a potentially improved approach to measuring deslorelin compared to existing techniques, although the clinical significance of these findings remains unclear. The study does not provide direct evidence of clinical outcomes or effects in humans, limiting its applicability in practice. The findings may be relevant primarily for research purposes.
Key findings
- Detectability optimized to <1 ppb.
- MALDI-TOF revealed binding by copper.
- Proposed method applicable to other GnRH superagonists.
Limitations
- Not reported in abstract.
- Focuses on analytical method rather than clinical outcomes.
- No human data reported.
- Potential confounding factors not addressed.